Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pharma consulting(ファーマコンサルティング)では、経験豊富なコンサルタントが弊社のデータベース群をフル活用し、かつ、外部の情報ソースも利用してお客様のニーズに合わせた個別の市場調査・分析を行います。
コンサルティングで下記のニーズにお応えします：
Pharma consultingご利用のメリットを1分間の動画にまとめました。ぜひご覧下さい。
インフォーマセミナー講演動画
Pharma consultingのシニアディレクター・Timothy Pangが、Pharma consultingサービスのケーススタディを交えて講演を行いました。
1. Bringing data alive: Consulting Case Studies(2018年2月／東京)
2. New horizons, fresh opportunities: Tech, Big Data, and the next pharma wave(2017年11月／東京)
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
05 Dec 2018
Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.
Topic BioPharmaceutical
Scrip: 世界の医療用医薬品＆製薬産業に関するニュース, Pink Sheet: 世界の薬事規制と承認審査に関するニ...
09 Nov 2018
Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
06 Sep 2018
Drug delivery technology specialist Consort Medical has capitalized on device respiratory expertise for 50 years, but a renewed focus on strategic expansion has seen it make an IP play, move into the pharma side and target other delivery formats for global pharma industry customers. Its enhanced capabilities will keep rivals on their toes.
Topic drug-review drug-approval
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
22 Aug 2018
The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
By Melanie Senior 22 Aug 2018
Experiments are underway to solve pharma’s well-documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up different kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in healthcare.
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
22 Aug 2018
Johnson & Johnson's DePuy Synthes orthopedic business has taken a measured view of digital and robotic capabilities, rather than acquiring assets that perhaps do not fully meet its strategic needs. For the business's global R&D head Euan Thomson, any new technology must augment the group's abilities to drive meaningful outcomes.
Topic digital-health
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
By William Looney 22 Aug 2018
The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
22 Aug 2018
Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
By William Looney 22 Aug 2018
The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.
Topic cancer
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
17 Aug 2018
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.
Topic drug-approval drug-review
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
By Amama Sadiq, Iliyana P. Atanasova, Katherine J. Franklin 03 Aug 2018
Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.
Topic Clinical trials
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
By William Looney 12 Jul 2018
Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer. In Vivo examines biopharma’s enduring optimism about the future of cancer vaccinology, including a closer look at one company’s platform to tackle the incurable malignancies that beset the mother of all organs: the human brain.
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
By William Looney 15 May 2018
On October 5, In Vivo convened a group of top market-access specialists and industry and investment analysts to consider a central strategic challenge facing all innovators in biopharma: how to pay for the next wave of cures. Finding the answer first depends on a rebranding of the function itself – it’s not market access to products; it’s patient access to progress.
Topic strategy
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
11 May 2018
Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise?In Vivotalks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value. (3) Work fast – spend forward. (4) Reach out earn the business.
Topic BioPharmaceutical
In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース
11 May 2018
Value is a concept that is increasingly embraced by providers and payers, as well as medtech manufacturers. Leading providers are organizing around value, changing their models and thereby inviting medtech manufacturers to adapt to the post fee-for-service era. Some, like Medtronic, are at the head of the game.
In Vivo: 医療用医薬品・医療機器...
21 Nov 2018
In Vivo: 医療用医薬品・医療機器...
21 Nov 2018
In Vivo: 医療用医薬品・医療機器...
19 Nov 2018
In Vivo: 医療用医薬品・医療機器...
14 Nov 2018
In Vivo: 医療用医薬品・医療機器...
08 Nov 2018
In Vivo: 医療用医薬品・医療機器...
29 Oct 2018
In Vivo: 医療用医薬品・医療機器...
24 Oct 2018
In Vivo: 医療用医薬品・医療機器...
24 Oct 2018
In Vivo: 医療用医薬品・医療機器...
23 Oct 2018
In Vivo: 医療用医薬品・医療機器...
23 Oct 2018
In Vivo: 医薬品・医療機器業界の...
17 Oct 2018
In Vivo: 医薬品・医療機器業界の...
17 Oct 2018
In Vivo: 医薬品・医療機器業界の...
15 Oct 2018
In Vivo: 医薬品・医療機器業界の...
15 Oct 2018
In Vivo: 医薬品・医療機器業界の...
10 Oct 2018
Timothy specializes in
+22 year(s) experience
Richard specializes in
+20 year(s) experience
お問い合わせ先
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
